The contribution of molecular genetics to colorectal cancer has been restricted largely to relatively rare inherited tumours and to the detection of germline mutations predisposing to these cancers. However, much is now also known about somatic events leading to colorectal cancer. A number of studies has been undertaken examining possible relations between genetic features and prognostic indices. While many of these studies are small and inconclusive, it is clear that a number of different pathways exist for the development of this cancer and some molecular characteristics correlate with clinicopathological features. With the advent of methods for the rapid genotyping of large numbers of colorectal cancers, it should be possible to evaluate fully the clinical usefulness of colorectal cancer genotypes through multivariate analyses. (7 Clin Pathol: Mol Pat/iol 1997;50:28 1 -288) 
R S Houlston, I P M Tomlinson Abstract The contribution of molecular genetics to colorectal cancer has been restricted largely to relatively rare inherited tumours and to the detection of germline mutations predisposing to these cancers. However, much is now also known about somatic events leading to colorectal cancer. A number of studies has been undertaken examining possible relations between genetic features and prognostic indices. While many of these studies are small and inconclusive, it is clear that a number of different pathways exist for the development of this cancer and some molecular characteristics correlate with clinicopathological features. With the advent of methods for the rapid genotyping of large numbers of colorectal cancers, it should be possible to evaluate fully the clinical usefulness of colorectal cancer genotypes through multivariate analyses. (7 Clin Pathol: Mol Pat/iol 1997;50:28 1 -288) Keywords: colorectal cancer; prognosis Colorectal cancer accounts for over 90% of the malignant tumours of the large bowel. After lung and breast cancer, it is the most common cause of death from malignant disease in western countries. The incidence of the disease in England and Wales is about 30 000 cases per year,' resulting in around 17 000 deaths per annum2 and it has been estimated that at least half a million cases of colorectal cancer occur each year worldwide.3 Incidence rates of the tumour are increasing in many countries. This, together with a reduction in smoking, may result in colorectal cancer becoming the most common cause of death from malignant disease in the near future. Unfortunately, despite improvements in medical and surgical provision, there has been little change in mortality from colorectal cancer during the past 40 Dukes 's system into categories A, B, C, and D.' Grade can either be expressed simply as degree of differentiation (well, medium, or poorly differentiated) or according to the more complex Jass grouping.6 Prognosis correlates well with both stage and grade.
Patients fall into two broad groups at time of presentation. The first group either have non-resectable cancers or disseminated disease. These patients have a very poor prognosis, with a median survival of seven months.3 The other two thirds of patients will undergo a resection of their primary tumour. Despite an apparently "curative" resection, around 50% of patients will die within five years, and of these around 80% will have had a detectable recurrence within two years. The majority of these patients die as a result of liver secondaries, but there is evidence that they also have widespread extrahepatic disease. mutations are rare in adenomas, suggesting that p53 plays a role in tumour progression, but it is not an absolute requirement for malignant transformation because a significant proportion of cases have no demonstrable abnormality. These mutations also tend to occur at the late adenoma stage (although they occur earlier in colorectal cancers associated with inflammatory bowel disease, which do not develop from adenomas).56 Dominant, gain of function mutations in p53 are common in colorectal cancers and these can be detected reliably using immunohistochemistry for p53 protein. 57 Mutations that are likely to be important prognostically are those that involve genes involved in tumour progression rather than initiation. Therefore, it is not surprising that allele loss at chromosome 5q, the site of the APC gene, has not been shown to be a prognostic marker.87 88 90 The high rate of allele loss at other chromosomes such as 8p, lp, and llq during tumour progression suggests that they may be sites of other tumour suppressor genes that are important for the progression of colonic tumours. A correlation between 8p allele loss and microinvasion (a prognostic marker independent of Dukes's stage) has been reported93 in one small study of 14 colorectal cancers. A relation between tumour progression and chromosome 1 deletions has also been shown.87 However, analysis of 126 sporadic colorectal cancers for allele loss at 11 q22 has failed to show an association with Dukes's grade or degree of differentiation.94 K RAS Along with p53, K ras mutations are one of the most common genetic lesions in human cancer. Since the discovery of the human ras gene family, there has been much debate concerning the potential for differential tumour behaviour as a result of different ras mutations. Point mutations in codons 12, 13, and 61 of the K ras gene are early events in the pathogenesis of colorectal cancer. However, the impact of the number, type, and position of such mutations on the progression of adenomas, as well as the clinical behaviour of colorectal carcinomas, is not fully established. To date, most studies have indicated that the second base of codon 12 is mutated more heavily in colorectal cancers than the first or the third bases. Therefore, it is conceivable that the type of K ras mutation determines tumour behaviour directly.
In a relatively large study by Finkelstein et al of 194 consecutive primary, recurrent, and metastatic colorectal adenocarcinomas, a significantly higher mutation rate in K ras was seen in lymphogenous, haematogenous metastases.95 When colorectal carcinomas were analysed by specific K ras mutation type, it was found that codon 13 mutated tumours did not progress to local or distant metastasis. Tumours having a codon 12 valine substitution did not metastasise beyond pericolonic, perirectal lymph nodes. In contrast, colorectal cancers with codon 12 aspartic acid substitutions accounted for most of the distant haematogenous deposits. Tumours with normal K ras accounted for most intraperitoneal deposits. On the basis of these data, Finkelstein et al proposed that genotyping of colorectal adenocarcinoma by K ras status would identify subsets of patients likely to pursue indolent or aggressive forms of disease.
Some, but not all, reports have supported the proposal that the possession of a K ras mutation is associated independently with shorter survival rates.9l'00 However, the relation between specific mutation and prognosis is unclear. Early in vitro observations suggested that codon 12 A systematic analysis of 215 sporadic colorectal cancer patients showed that those with microsatellite instability had a survival advantage over patients without it, independent of other prognostic factors."' Microsatellite instability was found in 16.4% of colorectal cancers. The hazard ratio of patients with tumours showing microsatellite instability to those without was estimated to be 0.39 (95% CI 0.19 to 0.82). At any point in time after diagnosis, a patient whose tumour displayed microsatellite instability had a risk of dying, which was approximately 39% of the risk of a patient with a tumour without microsatellite instability, even after allowing for the effect of other predictive factors. Only one of the 24 patients exhibiting microsatellite instability in their colorectal cancers possessed a detectable germline defect in hMSH2. These findings suggest that although the genetic basis of HNPCC and sporadic cancers with microsatellite instability is different, tumours in the two groups share some biological characteristics in terms of prognosis.
P53 AND P27
An increased intracellular concentration of p53, which is frequently but not always related to p53 mutation, has been proposed as being associated with poor prognosis in some tumour types. In immunohistochemical studies of colorectal cancer, although p53 overexpression correlates with chromosome 17p loss, hyperdiploid DNA content, and tumour site there have been conflicting findings about its role as a prognostic indicator."2-125 This reflects the fact that the degree of association between p53 mutations and protein expression depends, in part, on the specific antibody used. In studies of the relation between p53 mutations and prognosis, the situation is much clearer. Studies suggest strongly that colorectal cancers harbouring p53 mutations are more aggressive, are associated with a higher propensity for lymphatic and haematogenous spread, and have a worse prognosis. '6 132 p27 is a member of the cip/kip family of cyclin dependent kinase inhibitors, which bind to cyclin:cyclin dependent kinase (cdk) complexes and block progression through the cell cycle. p27 regulates progression from G, into S phase by binding to and inhibiting the cyclin E/Cdk2 complex, which is required for cells to enter S phase. In contrast to the p53 gene, mutations in p27 are rare. However, cell cycle regulation of p27 concentrations occurs at the post-transcriptional level through proteasome mediated degradation.'33 Recently, reduced expression of p27 has been shown to correlate with poor survival in a study of 149 patients with primary colorectal cancer. 134 Patients whose tumours expressed p27 had a median survival of 151 months, whereas those who lacked p27 (10%) had a median survival of only 69 months. In this study, p27 expression was shown to be an independent prognostic marker and the risk of death associated with reduced expression was increased 2.9-fold.
Conclusions
The incidence of colorectal cancer is increasing and, unfortunately, the prognosis remains poor for the majority of patients. Identification 
